HCC Associated with Viral Liver Infections (HBV, HCV, and HDV) and Other Rare Conditions
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".
Deadline for manuscript submissions: 11 December 2026 | Viewed by 756
Special Issue Editors
Interests: clinical and epidemiological features of chronic hepatitis C and B and its antiviral treatments; cirrhosis and complication of evolutive liver disease; natural history and treatment of hepatocellularcarcinoma; transient elastography for staging of chronic liver diseases; cardiac cirrhosis; Fontan associate liver disease
Special Issues, Collections and Topics in MDPI journals
Interests: clinical and epidemiological aspects of chronic hepatitis viral infections (HCV, HBV, HDV), high degree specialization on transient elastography staging of liver diseases in the setting of various etiologies (from viral agents to Metabolic associated steatotic liver disease, MASLD, and Fontan associated liver disease, FALD, and other rare liver vascular conditions determining liver injury)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and represents a major global health burden. It is currently a leading cause of cancer-related mortality worldwide, particularly in regions with a high prevalence of chronic hepatitis B virus (HBV), hepatitis C virus (HCV), and coinfections with HBV and HCV or with HBV and hepatitis D virus (HDV). However, HCC may also arise from numerous other etiological factors capable of inducing hepatocarcinogenesis. The development of HCC is typically the result of a multistep process involving chronic liver injury, persistent inflammation, oxidative stress, and compensatory regeneration, ultimately leading to cirrhosis, a key predisposing condition.
The aim of this Special Issue is to advance understanding of the epidemiology, etiopathogenesis, diagnostic approaches, and therapeutic strategies related to HCC associated with viral infections (HBV, HCV, and HDV), with the overarching goal of improving patient outcomes through earlier diagnosis and optimized clinical management. Original research articles presenting novel laboratory data and clinical evidence elucidating the pathogenesis, progression, or therapeutic targets of HCC are strongly encouraged. This includes mechanistic and translational studies conducted in cohorts with hepatitis virus infections (HCV, HBV, and HDV) known to drive HCC development, as well as in individuals exposed to hepatotoxic risk factors (e.g., alcohol, PHAS, drugs, and steatosis) that predispose to HCC. Submissions addressing other chronic liver conditions that act as key precancerous lesions for HCC are also welcome, including chronic cholestasis (e.g., PBS, PBC, and congenital defects of bile transporters) and vascular or congestive liver diseases (e.g., congenital heart disease-associated liver disease, Fontan-associated liver disease, Budd–Chiari syndrome, and portosystemic shunts).
Dr. Liliana Chemello
Dr. Luisa Cavalletto
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- viral infections
- hepatocarcinogenesis
- chronic liver damage
- epidemiology
- etiopathogenesis
- diagnostic approaches
- therapeutic strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
